- Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are highly prevalent multi-system disorders that represent major threats to public health.
- Improved knowledge of the metabolic etio-pathophysiology of NAFLD/NASH has stimulated intense efforts to develop safe and effective pharmacological interventions. Many of the drugs that have been evaluated as potential treatments for NAFLD/NASH or are currently in development are classified as having metabolic or cardiometabolic actions
- We propose a collaborative approach to the development of new pharmacotherapies for NAFLD/NASH that brings together expertise in clinical hepatology, diabetes and human metabolism